## VU0463271

Cat. No.:	HY-110110			
CAS No.:	1391737-01	-1		
Molecular Formula:	C <sub>19</sub> H <sub>18</sub> N <sub>4</sub> OS	2		
Molecular Weight:	382.5			
Target:	Potassium Channel			
Pathway:	Membrane Transporter/Ion Channel			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	2 years	
		-20°C	1 year	

®

MedChemExpress

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (65.36 mM; Need ultrasonic)						
Prepa Stock		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.6144 mL	13.0719 mL	26.1438 mL		
		5 mM	0.5229 mL	2.6144 mL	5.2288 mL		
		10 mM	0.2614 mL	1.3072 mL	2.6144 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent o Solubility: ≥ 2.5 m	one by one: 10% DMSO >> 90% cor g/mL (6.54 mM); Clear solution	n oil				

Description	VU0463271 is a selective KCC2 antagonist, with an IC $_{50}$ of 61 nM.			
IC <sub>50</sub> & Target	IC50: 61 nM (KCC2) <sup>[1]</sup> .			
In Vitro	VU0463271 is a potent antagonist of the neuronal-specific potassium-chloride cotransporter 2 (KCC2), with an IC <sub>50</sub> of 61 nM and >100-fold selectivity versus the closely related Na-K-2Cl cotransporter 1 (NKCC1) and no activity in a larger panel of GPCRs, ion channels and transporters. It is also found rapidly cleared in vitro <sup>[1]</sup> . VU0463271 is applied to the transected CNS preparation and resulted in a significant increase in firing rates of the Drosophila CNS with 1 µM VU0463271 resulting in a peak firing rate that was a 2.7- and 2.5-fold increase over baseline firing rate for OR and rdl strains, respectively <sup>[2]</sup> . VU0463271 (10-100 nM) results in approximately 20% reduction of CNS firing frequency within asmall percentage of preparations <sup>[2]</sup> .			

## Product Data Sheet

⊳<sub>N</sub>́N

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	VU0463271 is found to be a moderate-to-high clearance compound in rat (CL=57 mL/min/kg) following intravenous administration (1 mg/kg); the low volume of distribution at steady state (Vss 0.4 L/kg), coupled with moderate-to-high clearance produce a relatively short t1/2 (9 min) in vivo <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Delpire E, et al. Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4532-5.

[2]. Rui Chen, et al. Functional Coupling of K +-Cl - Cotransporter (KCC) to GABA-Gated Cl - Channels in the Central Nervous System of Drosophila melanogaster Leads to Altered Drug Sensitivities. ACS Chem Neurosci. 2019 Jun 19;10(6):2765-2776.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA